Clinical Pharmacogenetics of Irinotecan (CPT-11)
- 1 January 2005
- journal article
- review article
- Published by Taylor & Francis Ltd in Drug Metabolism Reviews
- Vol. 37 (3), 565-574
- https://doi.org/10.1080/03602530500316254
Abstract
Irinotecan (CPT-11) is now widely used, especially for colorectal and lung cancers, whereas the drug causes severe adverse drug reactions (ADR), such as leukopenia/neutropenia or diarrhea. Irinotecan undergoes drug metabolism to form an active SN-38, which is further converted to its β-glucuronide by UDP-glucuronosyltransferase (UGT) 1A1. A variant in the promoter of UGT1A1 gene, UGT1A1*28 allele, has been extensively studied, and pharmacogenetic relationships between the variant and ADR to irinotecan have been reported. A case-control study of Japanese cancer patients demonstrated that the patients having UGT1A1*28 were at significantly increased risk of severe ADR to irinotecan. To date, genetic variations of the UGT1A1 gene is the most important hereditary factor to predict severe ADR to irinotecan. The UGT1A1*28 is the only one variant that has multiple lines of clinical evidence in multiple races, whereas genetic variations of other UGT isoforms, drug-metabolizing enzymes and drug transporters need more confirmations of its clinical significance in multiple patient groups. At present, irinotecan chemotherapy based on a patient's UGT1A1 genetic status is scientifically reasonable.Keywords
This publication has 36 references indexed in Scilit:
- ABCG2 PharmacogeneticsClinical Cancer Research, 2004
- Irinotecan in Small-Cell Lung CancerNew England Journal of Medicine, 2002
- Genetic Polymorphisms of the UDP‐Glucuronosyltransferase 1A7 Gene and Irinotecan Toxicity in Japanese Cancer PatientsJapanese Journal of Cancer Research, 2002
- Polymorphisms of UDP-Glucuronosyltransferase and Pharmacokinetics of IrinotecanTherapeutic Drug Monitoring, 2002
- Pharmacokinetic, Metabolic, and Pharmacodynamic Profiles in a Dose-Escalating Study of Irinotecan and CisplatinJournal of Clinical Oncology, 2000
- The UGT1A1*28 allele is relatively rare in a Japanese populationPharmacogenetics, 1998
- UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecanAnnals of Oncology, 1998
- Racial variability in the UDP-glucuronosyltransferase 1 ( UGT1A1 ) promoter: A balanced polymorphism for regulation of bilirubin metabolism?Proceedings of the National Academy of Sciences of the United States of America, 1998
- The Genetic Basis of the Reduced Expression of Bilirubin UDP-Glucuronosyltransferase 1 in Gilbert's SyndromeNew England Journal of Medicine, 1995
- Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN-38 during phase I trialsAnnals of Oncology, 1995